勃林格殷格翰的思力华适合什么人用？

(Repimat) is a long-acting, specific anti-muscarinic drug, which is often called an anticholinergic drug in clinical practice. By binding to muscarinic receptors on bronchial smooth muscle, Slivar inhibits the cholinergic (bronchoconstrictor) effects of acetylcholine released from parasympathetic nerve terminals. It has similar affinity for muscarinic receptor subtypes M1-M5.

In the respiratory tract, Spiriva competitively and reversibly inhibits M3 receptors, causing smooth muscle relaxation. This effect is dose-dependent and lasts for more than 24 hours. The long duration of action may be due to its very slow dissociation from M3 receptors. Its dissociation half-life is significantly longer than ipratropium bromide. As a quaternary ammonium anticholinergic drug, tiotropium bromide is local (bronchial) selective when administered by inhalation, thereby achieving therapeutic effects without producing systemic anticholinergic effects. Its bronchodilatory effect is basically a local (airway) effect rather than a systemic effect.

In clinical practice, Boehringer Ingelheim's Slivar is mainly suitable for the treatment of patients with chronic obstructive pulmonary disease. Relevant studies have confirmed that the treatment of patients with moderate to severe adult chronic obstructive pulmonary disease (COPD) using Seretide combined with intravenous Slivar has an ideal effect, can improve clinical efficacy, and can bring into play the advantages of different regimens to improve clinical efficacy.

Boehringer Ingelheim officially entered the Chinese market in 1994. The UPLIFT and POET studies in 2008 and 2011 confirmed Slivar's leading position in the treatment of chronic obstructive pulmonary disease (COPD). Siliva has been registered and marketed in more than 100 countries around the world. In 2012, global sales reached US$4.5 billion. It has been verified by 25 million patients annually, accounting for 70% of the company's total sales. Silihua has professional craftsmanship, excellent quality, and excellent efficacy. Therefore, the 2013 GOLD guideline recommended it as the first choice for the treatment of stable COPD.

Recommended hot articles: /newsDetail/94294.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.